L Ahdieh

Summary

Affiliation: Johns Hopkins Bloomberg School of Public Health
Country: USA

Publications

  1. ncbi Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women
    L Ahdieh
    Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    Am J Epidemiol 151:1148-57. 2000
  2. ncbi When to initiate highly active antiretroviral therapy: a cohort approach
    Linda Ahdieh-Grant
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Am J Epidemiol 157:738-46. 2003
  3. ncbi Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women
    L Ahdieh
    Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 184:682-90. 2001
  4. ncbi Pregnancy and infection with human immunodeficiency virus
    L Ahdieh
    Johns Hopkins School of Hygiene and Public Health, Department of Epidemiology, 615 North Wolfe Street, Room E 7014, Baltimore, MD 21205, USA
    Clin Obstet Gynecol 44:154-66. 2001
  5. ncbi Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus
    L Ahdieh
    Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    Am J Epidemiol 152:923-33. 2000
  6. ncbi Clinical course of recurrent respiratory papillomatosis in Danish children
    Michael J Silverberg
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Otolaryngol Head Neck Surg 130:711-6. 2004
  7. ncbi Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women
    Raphael P Viscidi
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 187:194-205. 2003
  8. ncbi Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women
    Raphael P Viscidi
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 188:1834-44. 2003
  9. ncbi Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study
    Linda Ahdieh-Grant
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 38:500-3. 2005
  10. ncbi Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women
    Linda Ahdieh-Grant
    Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Rm E 7014, Baltimore, MD 21205, USA
    J Natl Cancer Inst 96:1070-6. 2004

Detail Information

Publications10

  1. ncbi Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women
    L Ahdieh
    Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    Am J Epidemiol 151:1148-57. 2000
    ..014) was fully explained by repeated HPV positivity induced by HIV infection (p = 0.648). Reversal of immunosuppression following potent antiretroviral therapy must be expected to have a dramatic impact on HIV-related CIN...
  2. ncbi When to initiate highly active antiretroviral therapy: a cohort approach
    Linda Ahdieh-Grant
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Am J Epidemiol 157:738-46. 2003
    ..Furthermore, results suggest a potential threshold for HAART initiation in the neighborhood of 275 cells/microl...
  3. ncbi Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women
    L Ahdieh
    Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 184:682-90. 2001
    ..9 (95% CI, 1.5-2.3) times greater if the subject had a CD4 cell count <200 cells/microL (vs. >500 cells/microL). Thus, HIV infection and immunosuppression play an important role in modulating the natural history of HPV infection...
  4. ncbi Pregnancy and infection with human immunodeficiency virus
    L Ahdieh
    Johns Hopkins School of Hygiene and Public Health, Department of Epidemiology, 615 North Wolfe Street, Room E 7014, Baltimore, MD 21205, USA
    Clin Obstet Gynecol 44:154-66. 2001
    ..We can anticipate that the resolution of these questions will continue to be of broad public health interest as the epidemic impacts increasing numbers of women, a large fraction of whom will be adolescents...
  5. ncbi Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus
    L Ahdieh
    Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    Am J Epidemiol 152:923-33. 2000
    ....
  6. ncbi Clinical course of recurrent respiratory papillomatosis in Danish children
    Michael J Silverberg
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Otolaryngol Head Neck Surg 130:711-6. 2004
    ..To evaluate the clinical course of juvenile-onset recurrent respiratory papillomatosis (RP) with respect to age, disease duration, and maternal condylomas...
  7. ncbi Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women
    Raphael P Viscidi
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 187:194-205. 2003
    ..Despite the higher prevalence of HPV infection in this group, most HIV-positive women are able to control HPV-16 replication at the cervix, and reactivation, if it occurs, is not very common...
  8. ncbi Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women
    Raphael P Viscidi
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 188:1834-44. 2003
    ..9-5.4]), but there was no difference in the risk of incident HPV 16 or HPV 16-related infections. This may be evidence of partial type-specific or clade-specific immunity conferred by seropositivity to HPV 16 capsids...
  9. ncbi Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study
    Linda Ahdieh-Grant
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 38:500-3. 2005
    ..074, respectively). The increasing risk of HAART discontinuation in recent calendar periods and changes in the clinical factors associated with discontinuation reflect ongoing and dynamic shifts in the approach to HAART utilization...
  10. ncbi Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women
    Linda Ahdieh-Grant
    Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Rm E 7014, Baltimore, MD 21205, USA
    J Natl Cancer Inst 96:1070-6. 2004
    ..We assessed the association between use of highly active antiretroviral therapy (HAART) and regression of SIL in HIV-infected women enrolled in the Women's Interagency HIV Study, a large, multicenter, prospective cohort study...